Eli Lilly swoops in to buy a small protein drug developer and its glucose responsive insulin in $1B-plus deal
Eight months after taking the lead on an investment in Protomer Technologies and its glucose responsive insulin, Eli Lilly is coming back for the whole …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
